<I>In Vitro</I> Induction of Adipose-Derived Mesenchymal Stem Cells Differentiated Into Sweat Gland Epithelial Cells

Abstract

Objective: In order to provide basis for the in vitro construction of eccrine sweat gland tissue, we induced the adipose-derived mesenchymal stem cells (ADSCs) to differentiate into sweat gland epithelial cells (SGECs). Methods: ADSCs were isolated and cultured in vitro. The expressions of CD29, CD34, CD45, CD90 and CD105 were detected by flow cytometry. ADSCs were induced to differentiate into osteocytes and lipocytes by osteogenic and adipogenic liquid respectively. The obtained osteocytes and lipocytes were identified by alkaline phosphatase and oil red O staining. ADSCs cultured to the third generation were treated with DMEM (10% fetal calf serum and 40 ng/ml hepatocyte growth factor (HGF)) and induced to differentiate into SGECs in matrigel. Results: The cultured ADSCs proliferated well with fusiform shape. The detection results by flow cytometry indicated that the positive rates of CD29, CD90, CD105, CD34 and CD45 were 86.4%, 97.7%, 89.8%, 3.7% and 2.3%, respectively. The induced cells presented the phenotypic characteristics of the lipocytes and osteocytes after directed induction. The characteristics of SGECs can be observed in Matrigel 5 days after treated by 40 ng/mL HGF. Conclusion: ADSCs can differentiate into SGECs which shows the possibility of constructing sweat gland tissue in vitro.

A Computational QSAR, Molecular Docking and In Vitro Cytotoxicity Study of Novel Thiouracil-Based Drugs with Anticancer Activity against Human-DNA Topoisomerase II

“…The potential of the four TUDHIPP derivatives as antitumor agents was explored using density functional theory (DFT) computational approach, molecular docking simulation, virtual screening and drug likeness, and biochemistry techniques to evaluate the antitumor activity evaluated in the form of IC50. The drug design process requires several years for lead identification, optimization [ 12 ], and in vitro and in vivo testing [ 13 , 14 , 15 , 16 , 17 , 18 ] before the first clinical trials [ 19 , 20 ]. A large set of complex data with remarkable uncertainty levels is produced during the process of drug discovery [ 21 ].…”

Density Functional Theory, Chemical Reactivity, Pharmacological Potential and Molecular Docking of Dihydrothiouracil-Indenopyridopyrimidines with Human-DNA Topoisomerase II

“…The process of drug development is not straightforward, time-consuming, and cost intensive. It requires several years for lead identification, optimization [14], and in vitro and in vivo [15][16][17][18][19][20] testing before the first clinical trials [21,22]. During the process of drug discovery, a huge set of complex data with remarkable uncertainty levels is produced [23].…”